Patricia Millican
No más puestos en curso
Fortuna: 60 735 $ al 31/05/2023
Perfil
Patricia M.
Millican held several finance and accounting positions in the pharmaceutical industry, including Director at Amunix Pharmaceuticals, Chief Accounting Officer & Controller at Metabasis Therapeutics, Vice President-Finance at Aragon Pharmaceuticals, and Senior Vice President-Finance at Seragon Pharmaceuticals.
She also served as Chief Financial & Accounting Officer at Metacrine, Inc. Millican received her undergraduate degree from the University of San Diego.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
METACRINE INC
0.26% | 03/02/2023 | 109 040 ( 0.26% ) | 60 735 $ | 31/05/2023 |
Antiguos cargos conocidos de Patricia Millican.
Empresas | Cargo | Fin |
---|---|---|
METACRINE, INC. | Director of Finance/CFO | 31/03/2022 |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Director/Board Member | 01/02/2022 |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/08/2013 |
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Comptroller/Controller/Auditor | 11/09/2009 |
Seragon Pharmaceuticals, Inc.
Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Director of Finance/CFO | - |
Formación de Patricia Millican.
University of San Diego | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Health Technology |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
Seragon Pharmaceuticals, Inc.
Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
Metacrine, Inc. |
- Bolsa de valores
- Insiders
- Patricia Millican